Peter Clark
Northern General Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Peter Clark.
Atherosclerosis | 2000
Naveed Sattar; Peter Clark; Ian A. Greer; James Shepherd; Chris J. Packard
Lipoprotein (a) (Lp(a)) is recognised as a risk factor for arterial and venous thrombosis, a property which may relate to its structural similarity to plasminogen. Pregnancy is associated with a hypofibrinolytic state. Elevated Lp(a) may influence fibrinolysis and have an unfavourable role in pregnancy outcome. In this study alterations in plasma Lp(a) concentrations during normal pregnancy was examined, in a detailed longitudinal investigation, in ten women together with changes in other lipid parameters. In addition, Lp(a) concentrations were examined in subjects with pre-eclampsia (n=10) relative to matched controls (n=10), since it has recently been reported that a substantial increase in circulating Lp(a) occurs in this disorder. Lp(a) concentration increased steadily in normal pregnancy between 10 and 35 weeks with a doubling of the median value from 14.5 to 27.0 mg/dl (P=0.01). A significant increase in Lp(a) values was observed in all subjects with increasing gestation (median rise 190%, range 117-340%). This increase was intermediate to those seen in plasma triglyceride and cholesterol. No significant difference in Lp(a) values was observed in subjects with pre-eclampsia, compared with matched normal pregnancy controls (median 14 mg/dl [IQR 4.7-69.0] in pre-eclampsia vs 20 mg/dl [9.0-56. 3] in controls; P=0.57), at a median gestation of 32 weeks. In conclusion, there is a 2-fold increase in Lp(a) during normal pregnancy, which may influence fibrinolysis. Circulating Lp(a) is not significantly elevated in women with pre-eclampsia, and thus is unlikely to play a role in the pathophysiology of this disorder.
The Lancet | 1999
Peter Clark; Richard Eastell; Margo E. Barker
We supplemented the diets of 47 peripubertal girls with zinc (15 mg/day) or placebo for 6 weeks. Zinc supplementation increased serum zinc. Insulin-like growth factor I and biochemical markers of bone turnover did not change, albeit dietary zinc was below the reference level (in 94% of individuals).
Thrombosis and Haemostasis | 2001
Peter Clark; Naveed Sattar; Isobel D. Walker; Ian A. Greer
The Lancet | 1999
Peter Clark; Isobel D. Walker; Ian A. Greer
Seminars in Thrombosis and Hemostasis | 2003
Peter Clark; Ian A. Greer
Thrombosis and Haemostasis | 2003
Peter Clark; Fiona Jordan; Charles Pearson; Isobel D. Walker; Naveed Sattar; Joanne Ellison; Ian A. Greer
Archive | 2005
Peter Clark; Ian Greer
Archive | 2005
Peter Clark; Ian Greer
Archive | 2014
Sonia Whyte; Ian Greer; Peter Clark; I. D. Walker; Peter Langhorne; Lena Crichton; Andrew Thomson; M. Greaves
Archive | 2005
Peter Clark; Ian Greer